

CSD/BSE&NSE/BM/2022-23
February 6, 2023

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. February 6, 2023, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and nine months ended 31st December, 2022.

We are enclosing herewith the following documents:

- 1) Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022
- 2) Limited Review Reports on the financial results as mentioned above and
- 3) Earnings Presentation of our company to investors

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:55 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited

**STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED
31st DECEMBER ' 2022.**

		Rs.in Lacs					
PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the Year Ended
		31/12/2022	30-09-22	31/12/2021	31/12/2022	31-12-21	31-03-22
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	34,848.90	27,840.18	39,158.53	96,568.99	95,637.49	132,022.21
	Other Income	1,251.05	1,038.94	927.43	3,379.74	5,339.22	18,778.80
	Total income	36,099.95	28,879.12	40,085.96	99,948.73	100,976.71	150,801.01
2	Expenses						
	a) Cost of materials consumed	13,516.42	8,433.67	11,847.97	33,179.49	32,917.83	45,945.64
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,650.99)	33.02	96.07	(4,182.10)	(4,041.18)	(6,035.21)
	d) Employee benefits expense	2,726.37	2,588.69	2,500.87	7,794.32	6,936.19	10,048.39
	e) R & D expense	226.99	207.46	218.85	657.68	821.03	1,035.45
	f) Finance costs	137.94	29.03	74.17	310.22	404.23	623.10
	g) Depreciation and amortisation expenses	1,091.38	1,075.57	1,050.60	3,221.73	2,867.63	3,909.71
	h) Manufacturing Expenses	4,599.26	4,449.52	4,625.81	13,187.47	12,884.52	17,318.86
	i) Other Expenses	1,724.14	1,463.55	1,266.16	5,087.18	3,877.14	5,710.25
	Total expenses	21,371.51	18,280.51	21,680.50	59,255.99	56,667.39	78,556.19
3	Profit before exceptional items & Tax (1-2)	14,728.44	10,598.61	18,405.46	40,692.74	44,309.32	72,244.82
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	14,728.44	10,598.61	18,405.46	40,692.74	44,309.32	72,244.82
6	Tax Expenses						
	a) Current tax	3,715.23	2,562.47	4,620.66	10,165.80	10,615.02	15,763.03
	b) Deferred tax	66.59	143.86	85.27	282.87	330.89	671.91
7	Net Profit/ (Loss) for the period/year(5-6)	10,946.62	7,892.28	13,699.53	30,244.07	33,363.41	55,809.88
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(25.48)	(25.49)	(27.95)	(76.45)	(83.89)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.41	6.42	7.03	19.24	21.11	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(19.07)	(19.07)	(20.92)	(57.21)	(62.78)	(76.29)
9	Total Comprehensive Income for the period (7+8)	10,927.55	7,873.21	13,678.61	30,186.86	33,300.63	55,733.59
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
11	Other Equity	-	-	-	-	-	149,523.67
12	Earning Per Share (EPS)-Face value of Rs.1/- each)						
	a) Basic	4.30	3.10	5.38	11.88	13.11	21.92
	b) Diluted	4.30	3.10	5.38	11.88	13.11	21.92
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the Year Ended
		31/12/2022	30-09-22	31/12/2021	31/12/2022	31-12-21	31-03-22
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
	(1)	(2)	(3)	(4)	(5)	(4)	
1	Income						
	Revenue from operations	35,377.17	27,840.18	39,158.53	97,097.26	95,637.49	132,022.21
	Other Income	1,301.12	1,092.00	6,468.51	3,496.43	7,550.91	9,238.03
	Total income	36,678.29	28,932.18	45,627.04	100,593.69	103,188.40	141,260.24
2	Expenses						
	a) Cost of materials consumed	13,603.62	8,575.01	11,847.97	33,452.18	32,917.83	45,945.64
	b) Purchases of stock-in-trade			-			
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,639.91)	21.93	96.07	(4,182.11)	(4,041.18)	(6,035.21)
	d) Employee benefits expense	2,967.54	2,864.78	2,500.87	8,490.88	6,936.19	10,048.39
	e) R & D expense	226.98	207.46	218.85	657.67	821.03	1,035.45
	f) Finance costs	138.27	29.34	74.17	312.77	404.23	623.10
	g) Depreciation and amortisation expense	1,223.90	1,203.05	1,050.60	3,577.41	2,867.63	3,909.71
	h) Manufacturing Expenses	4,736.40	4,614.82	4,625.81	13,582.17	12,884.52	17,318.86
	i) Other Expenses	1,813.06	1,568.24	1,266.91	5,350.83	3,878.61	5,766.55
	Total expenses	22,069.86	19,084.63	21,681.25	61,241.80	56,668.86	78,612.49
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	14,608.43	9,847.55	23,945.79	39,351.89	46,519.54	62,647.75
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-	4,111.23	4,111.23
5	Profit before exceptional items , Tax (3+4)	14,608.43	9,847.55	23,945.79	39,351.89	50,630.77	66,758.98
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	14,608.43	9,847.55	23,945.79	39,351.89	50,630.77	66,758.98
8	Tax Expenses						
	a) Current tax	3,769.77	2,498.06	6,843.36	10,337.11	13,075.93	19,040.47
	b) Deferred tax	66.60	143.86	1,095.53	282.88	1,341.15	2,338.02
9	Net Profit/ (Loss) for the period/year(7-8)	10,772.06	7,205.63	16,006.90	28,731.90	36,213.69	45,380.49
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(25.60)	(25.60)	(27.95)	(76.77)	(83.89)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.41	6.42	7.03	19.24	21.11	25.66
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(19.19)	(19.18)	(20.92)	(57.53)	(62.78)	(76.29)
11	Total Comprehensive Income for the period (9 + 10)	10,752.87	7,186.45	15,985.98	28,674.37	36,150.91	45,304.20
12	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity	-	-	-	-	-	150,172.39
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)						
	a) Basic -	4.23	2.83	6.29	11.29	14.23	17.83
	b) Diluted	4.23	2.83	6.29	11.29	14.23	17.83
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



Notes 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th February, 2023. The above results have been subjected to limited review by the statutory auditors of the company.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (wef from 22nd April '2022).

4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (Q4) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary.

6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US \$41.555 Mn and a stake valued at US \$15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021

7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US \$20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.

8) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022.

9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD



VENKAT JASTI

Managing Director

DIN: 00278028

Place : Hyderabad

Date : 6 th February ' 2023





**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
UNAUDITED STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN PHARMACEUTICALS LIMITED**, ("the Company") for the quarter and Nine months ended December 31, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended,

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of the company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the companies act 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 5 below nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial information of the USA branch included in the unaudited standalone financial results, who's interim financial information reflects Total revenues of Rs. Nil for the period ended Nine months and quarter ended December 31, 2022 and Total loss of Rs. (770.04) Lakhs and Rs. (309.67) Lakhs for the period ended Nine months and quarter ended December 31, 2022, respectively as considered in the Statement. This interim financial information has been



06/02/2023

reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these branch , is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO

Chartered Accountants

(Firm Registration No .001757S)



AJAY KUMAR KOSARAJU

Partner

M.No. 021989

UDIN: 23021989BGRFKF1320



Place: Hyderabad

Date : 06/02/2023

06/02/2023



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN PHARMACEUTICALS LIMITED** ("the Holding Company") and its subsidiaries (the Holding company and its subsidiaries together referred to as "the Group") for the quarter ended and Nine months ended December 31, 2022 (the "Statement") attached herewith, being submitted by the Holding company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Listing Regulations')

2. This Statement, which is the responsibility of the Holding company's Management and approved by the Holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Pharma Inc	Wholly Owned Subsidiary
Casper pharma private limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.




06/02/2023

6. We did not review the interim financial information of the subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 644.97 Lakhs and Rs.578.34 Lakhs for the period ended nine months and quarter ended 31st December,2022 respectively and Net loss after tax of Rs.(1512.16) Lakhs and Rs.(174.55) Lakhs for the period ended Nine months and quarter ended December 31, 2022 respectively, and Total comprehensive loss of Rs.(1512.48) Lakhs and Rs.(174.66) Lakhs for the period ended Nine months and quarter ended 31st December,2022 respectively as considered in the Statement. This interim financial information have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement is not modified in respect of the above matters.

For **KARVY & CO**
Chartered Accountants
(Firm Registration No .001757S)


AJAY KUMAR KOSARAJU
Partner
M.No. 021989
UDIN: 23021989BGRFKG2694



Place: Hyderabad
Date: February 06th 2023.

06/02/2023



SUVEN PHARMA

Earnings Presentation
Q3 & 9 months FY23





Risk Statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



4

Operation &
Financial
Performance
Q3FY23




14

Company
Background

Table of Contents




Operation & Financial Performance Q3FY23

Businesswise data



Note: Figures in INR Crore

Businesswise data





Note: Figures in INR Crore

Financial Snapshot


Q3FY23*

9MFY23


Growth in
Revenue



Growth in
EBITDA



Growth in
PAT



*Compared to previous quarter

Key Ratios

Q3FY23*


9MFY23

Growth in
EBIT




39.88%

EBITDA to
Income




44.20%


PAT to
Income




30.32%



-8.30%







44.25%



30.26%





*Compared to previous quarter

Financials Q3FY23





Note: Figures in INR Million

Financials 9MFY23





Note: Figures in INR Million

Financials Q3FY23



Financials 9MFY23



Financial Snapshot – Q3 and 9 months FY23

	Quarter ended			Period ended		Previous year
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
Revenue from operations	3,484.89	2,784.02	3,915.85	9,656.90	9,563.75	13,202.22
Other Income	125.11	103.89	92.74	337.97	533.92	1,877.88
Total income	3,610.00	2,887.91	4,008.60	9,994.87	10,097.67	15,080.10
EBITDA	1,595.78	1,170.32	1,953.02	4,422.47	4,758.12	7,677.76
EBITDA Margin	44.20%	40.52%	48.72%	44.25%	47.12%	50.91%
EBIT	1,486.64	1,062.76	1,847.96	4,100.30	4,471.36	7,286.79
EBIT Margin	41.18%	36.80%	46.10%	41.02%	44.28%	48.32%
Finance costs	13.79	2.90	7.42	31.02	40.42	62.31
Depreciation	109.14	107.56	105.06	322.17	286.76	390.97
Taxes	378.18	270.63	470.59	1,044.87	1,094.59	1,643.49
Taxes to PBT	25.68%	25.53%	25.57%	25.68%	24.70%	22.75%
PAT (Standalone)	1,094.66	789.23	1,369.95	3,024.41	3,336.34	5,580.99
PAT Margin (Standalone)	30.32%	27.33%	34.18%	30.26%	33.04%	37.01%
Associate Company	-	-	-	-	411.12	411.12
PAT (Consolidated)	1,077.21	720.56	1,600.69	2,873.19	3,621.37	4,538.05
PAT Margin (Consolidated)	29.84%	24.95%	39.93%	28.75%	35.86%	30.09%
EPS (Standalone)	4.30	3.10	5.38	11.88	13.11	21.92
EPS (Consolidated)	4.23	2.83	6.29	11.29	14.23	17.83
Paid up share capital (Re.1/sh)	254.56	254.57	254.57	254.56	254.57	254.56

All figures are in INR Million, other than ratios and EPS

Company Background

Business Model



Brief Profile

BUSINESS OVERVIEW

- Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.

KEY STRENGTHS

- Preferred global outsourcing partner with capabilities across the entire CDMO value chain.
- Strong chemistry skills.

FINANCIAL OVERVIEW

- Standalone Revenues, EBIT and PAT of Rs 9995 Mn, Rs 4100 Mn and Rs 3024 Mn in 9MFY23.

Overview

Suven is an integrated Contract Development and Manufacturing Operations company

Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

Since our founding in 1989 (pre-demerger), Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.

Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.


Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.

Our Focus

A full-fledged bio-pharmaceutical solutions provider for global pharmaceutical companies




Financial Approach




Business Drivers

Industry Relationship




Business Drivers

Execution Capabilities



Multi Location Facilities

Vizag, Andhra Pradesh, India



- 307 KL reactor volume
- 3KL to 12KL Reactors
- GL/SS (45No's)
- API's/Advanced Intermediate's/CMO

**Pashamylaram, Telangana, India
API & Formulation Facility**



- 120 kL reaction volume
- 50L – 6000 L GL/SS (45)
- API Manufacturing
- Formulation R&D


**Banjara Hills, Hyderabad, India
Corporate Office**



- Process Research
- Discovery R&D, Analytical R&D
- Killo lab, 30L CM Reactors (32)
- 50L – 4000 L GL/SS

**Jeedimetla, Telangana, India
R&D–Pilot Plant**

**Suryapet, Telangana, India
Intermediate Mfg. Facility**



- 300 CM reactors (93)
- 500L to 10 KL GL/SS
- GMP Intermediates
- Business Development
- Project Management
- Intellectual Property Management

**USA, New Jersey
Business Office**

Contact

Suven Pharmaceuticals Ltd

8-2-334, SDE Serene Chambers,
3rd Floor, Road No. 5, Avenue - 7, Banjara
Hills, Hyderabad-500 034, Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

**For queries and requests, please
contact:**

Sunder Venkatraman
Suven Pharmaceuticals Ltd

Tel: +91 939 248 3011

Email: info@suvenpharm.com

For more info: www.suvenpharm.com

Gavin Desa / Rishab Barar

CDR - India

Tel: +91 22 6645 1237 / 1235

Email: gavin@cdr-india.com

rishab@cdr-india.com